A phase I study of weekly topotecan (T) in combination with sorafenib (S) for treatment of relapsed or refractory small cell lung cancer (SCLC).

被引：0
|
作者：
Leach, J. W.
Swenson, K.
Anderson, E.
Menge, M. R.
Tsai, M. L.
机构：
[1] Pk Nicollet Inst, St Louis Pk, MN USA
[2] Frauenshuh Canc Ctr, Pk Nicollet Inst, St Louis Pk, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18086
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of weekly topotecan (T) in recurrent small cell lung cancer (SCLC)
    Groteluschen, D
    Traynor, A
    Schiller, J
    Dubey, S
    Hoang, T
    Kim, K
    Hansen, R
    Kwong, R
    Hammes, L
    Liverseed, K
    LUNG CANCER, 2005, 49 : S320 - S320
  • [2] A phase I study of weekly oral topotecan in patients (pts) with relapsed small cell lung cancer (SCLC)
    Kontopodis, E.
    Vamvakas, L.
    Kalbakis, K.
    Vardakis, N. K.
    Sfakiotaki, G.
    Georgoulias, V.
    Agelaki, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Doxorubicin and Topotecan for Relapsed/Refractory Small Cell Lung Cancer (SCLC): A FPBCC Clinical Trials Network Phase I Study
    Umakanthan, J. Manikkam
    Marr, A.
    Ernani, V.
    Kessinger, M.
    Smith, L.
    Tijerina, J.
    Radniecki, S.
    Kosmacek, E.
    Ketcham, M.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2188 - S2188
  • [4] Phase I study of the topotecan and epirubicin combination as second line treatment in small cell lung cancer (SCLC).
    Mavroudis, D
    Rapti, A
    Ardavanis, G
    Kouroussis, C
    Kakolyris, S
    Kalbakis, K
    Vardakis, N
    Vamvakas, L
    Klapsinos, N
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 120 - 120
  • [5] Late phase II trials of topotecan (T) for relapsed small cell lung cancer (SCLC)
    Nishiwaki, Y
    Negoro, S
    Watanabe, K
    Fukuoka, M
    Niitani, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S253 - S253
  • [6] Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC)
    Ardizzoni, A
    Hansen, HH
    Dombernowsky, P
    Kaplan, S
    Postmus, PE
    Gamucci, T
    Schaefer, B
    Wanders, J
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 84 - 84
  • [7] A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer
    S. Agelaki
    E. Kontopodis
    A. Kotsakis
    V. Chandrinos
    I. Bompolaki
    Ζ. Zafeiriou
    E. Papadimitraki
    D. Stoltidis
    K. Kalbakis
    V. Georgoulias
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 45 - 51
  • [8] A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer
    Agelaki, S.
    Kontopodis, E.
    Kotsakis, A.
    Chandrinos, V.
    Bompolaki, I.
    Zafeiriou, Z.
    Papadimitraki, E.
    Stoltidis, D.
    Kalbakis, K.
    Georgoulias, V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 45 - 51
  • [9] Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
    Heist, Rebecca Suk
    Fain, Jerry
    Chinnasami, Bernard
    Khan, Waseem
    Molina, Julian R.
    Sequist, Lecia V.
    Temel, Jennifer S.
    Fidias, Panos
    Brainerd, Valari
    Leopold, Lance
    Lynch, Thomas J.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1637 - 1643
  • [10] Cisplatin-topotecan-paclitaxel weekly administration in ovarian (OC) and small cell lung cancer (SCLC). A phase I study
    Frasci, G
    Comella, P
    Carteni, G
    Panza, N
    Guida, T
    Nicolella, GP
    Lombardi, R
    Pacilio, C
    Gravina, A
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 69 - 70
12345